Developer of a decentralized derivatives exchange protocol designed to create a free and inclusive financial system.
Developer of a decentralized derivatives exchange protocol designed to create a free and inclusive financial system.
Other Financial Services📍 Hong Kong, Hong KongFounded 2018
Current Valuation
$1.0B
as of 2021-Q2
UNICORN
QL Price
$1.0B
0% vs last round
QuantLogix's current estimate for Injective, published 2026-09-27 — in line with the last disclosed round of $1.0B (2021-Q2).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.0B
2021-Q2
weight 0.03
How this price has held up
No round has priced for Injective since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Injective, 2026-09-27 (22cd24c977b542e0).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Injective going public?
No. Injective is private and has not filed to go public. There is no S-1 on file.
What is Injective's valuation in 2026?
Injective is valued at $1.0B as of 2021-Q2, set by its Seed VC - II ($10M, Apr 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Injective filed an S-1?
No public S-1 is on file for Injective.
How much has Injective raised?
Injective has raised $13.1M in total, most recently a Seed VC - II of $10M in Apr 2021.
Is Injective publicly traded — can you buy Injective stock?
No. Injective is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Injective on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
Hong Kong, Hong Kong
Employees
140
Total Raised
$13.1M
Last Round
Seed VC - II — $10M (Apr 2021)
IPO Status
private
Fundraising Status
Seed VC - II · $10M · 5y 5mo ago
privateTotal raised $13.1M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Seed VC - II
$10M
Apr 2021
—
$1.0B
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
41
via workable
Product-build share
0%
engineering, research, product, design
Trajectory
steady
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (21 of 41 open roles are other).
Counted from Injective's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BlockchainCryptocurrencyFinanceInternet
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.